⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for rucaparib

Every month we try and update this database with for rucaparib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast TumorsNCT03911453
Breast Cancer
Rucaparib
21 Years - University of Arizona
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationNCT02042378
Pancreatic Canc...
Pancreatic Duct...
Rucaparib
18 Years - pharmaand GmbH
Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva CombinationNCT03462212
Advanced (Stage...
Carboplatin
Paclitaxel
Bevacizumab
Rucaparib
18 Years - Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsNCT04227522
Ovarian Cancer
Fallopian Tube ...
Primary Periton...
Clear Cell Carc...
Rucaparib
Placebos
18 Years - North Eastern German Society of Gynaecological Oncology
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerNCT04253262
Metastatic Cast...
Rucaparib
Copanlisib
18 Years - Brown University
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)NCT03694262
Endometrial Can...
Uterine Carcino...
Rucaparib
Bevacizumab
Atezolizumab
18 Years - Medical College of Wisconsin
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02975934
Metastatic Cast...
Rucaparib
Abiraterone ace...
18 Years - pharmaand GmbH
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral ContraceptivesNCT03954366
Neoplasms
Rucaparib
Rosuvastatin
Oral Contracept...
18 Years - pharmaand GmbH
Pan Tumor Rollover StudyNCT03899155
Cancer
Nivolumab
Ipilimumab
Cabozantinib
Trametinib
Relatlimab
Nivolumab + Rel...
Capecitabine
Bevacizumab
Temozolomide
Rucaparib
Daratumumab
Regorafinib
Leucovorin
Fluorouracil
Oxaliplatin
Enzalutamide
Sunitinib
Pemetrexed
Pembrolizumab
18 Years - Bristol-Myers Squibb
Pan Tumor Rollover StudyNCT03899155
Cancer
Nivolumab
Ipilimumab
Cabozantinib
Trametinib
Relatlimab
Nivolumab + Rel...
Capecitabine
Bevacizumab
Temozolomide
Rucaparib
Daratumumab
Regorafinib
Leucovorin
Fluorouracil
Oxaliplatin
Enzalutamide
Sunitinib
Pemetrexed
Pembrolizumab
18 Years - Bristol-Myers Squibb
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based TherapyNCT03140670
Pancreatic Canc...
RUCAPARIB
18 Years - Abramson Cancer Center at Penn Medicine
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerNCT03101280
Gynecologic Neo...
Atezolizumab
Rucaparib
18 Years - Hoffmann-La Roche
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)NCT01968213
Ovarian Cancer
Fallopian Tube ...
Peritoneal Canc...
Rucaparib
Placebo
18 Years - pharmaand GmbH
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerNCT03559049
Stage IV Non-sm...
Pembrolizumab
Pemetrexed
Carboplatin
Rucaparib
18 Years - University of Michigan Rogel Cancer Center
Rucaparib Maintenance Therapy in Advanced Cervical CancerNCT03795272
Cervical Cancer
Rucaparib
Placebo
18 Years - 100 YearsNordic Society of Gynaecological Oncology - Clinical Trials Unit
Rucaparib in Nonmetastatic prOstAte With BRCAnessNCT03533946
Prostate Cancer
Rucaparib
18 Years - University of Utah
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerNCT04253262
Metastatic Cast...
Rucaparib
Copanlisib
18 Years - Brown University
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial CarcinomaNCT03397394
Bladder Cancer
Urothelial Carc...
Metastatic Urot...
Renal Pelvis Ca...
Ureter Carcinom...
Urinary Bladder...
Urethra Carcino...
Muscle Invasive...
Rucaparib
18 Years - pharmaand GmbH
CATCH-R: A Rollover Study to Provide Continued Access to RucaparibNCT04676334
Metastatic Cast...
Ovarian Cancer
Epithelial Ovar...
Fallopian Tube ...
Peritoneal Canc...
Other Solid Tum...
Rucaparib
18 Years - pharmaand GmbH
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based TherapyNCT03140670
Pancreatic Canc...
RUCAPARIB
18 Years - Abramson Cancer Center at Penn Medicine
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid TumorNCT03499444
Advanced Solid ...
Rucaparib
20 Years - pharmaand GmbH
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyNCT03442556
ATM Gene Mutati...
BRCA1 Gene Muta...
BRCA2 Gene Muta...
Castration Leve...
Castration-Resi...
Homologous Reco...
Prostate Carcin...
PSA Level Great...
PSA Progression
Stage IV Prosta...
Carboplatin
Docetaxel
Laboratory Biom...
Rucaparib Camsy...
Rucaparib
18 Years - University of Washington
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.NCT03840200
Breast Cancer
Prostate Cancer
Ovarian Cancer
Ipatasertib
Rucaparib
18 Years - Hoffmann-La Roche
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)NCT03824704
Epithelial Ovar...
Fallopian Tube ...
Primary Periton...
High Grade Sero...
Endometrioid Ad...
Rucaparib
Nivolumab
18 Years - pharmaand GmbH
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerNCT03559049
Stage IV Non-sm...
Pembrolizumab
Pemetrexed
Carboplatin
Rucaparib
18 Years - University of Michigan Rogel Cancer Center
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)NCT01891344
Ovarian Cancer
Epithelial Ovar...
Fallopian Tube ...
Peritoneal Canc...
Oral rucaparib
18 Years - pharmaand GmbH
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsNCT04276376
Solid Tumor
Atezolizumab
Rucaparib
18 Years - Gustave Roussy, Cancer Campus, Grand Paris
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsNCT04227522
Ovarian Cancer
Fallopian Tube ...
Primary Periton...
Clear Cell Carc...
Rucaparib
Placebos
18 Years - North Eastern German Society of Gynaecological Oncology
Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 MonthsNCT04826198
Ovarian Cancer
AsiDNA
Niraparib
Olaparib
Rucaparib
18 Years - Gustave Roussy, Cancer Campus, Grand Paris
Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-RucaparibNCT02986100
Solid Tumor
C-14 labeled Ru...
Rucaparib
18 Years - pharmaand GmbH
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyNCT03542175
Breast Cancer
Rucaparib
Radiotherapy
18 Years - Memorial Sloan Kettering Cancer Center
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO StudyNCT04539327
Epithelial Ovar...
Fallopian Tube ...
Primary Periton...
Rucaparib
18 Years - Grupo Español de Investigación en Cáncer de Ovario
Combination Rucaparib With Nivolumab in Small Cell Lung CarcinomaNCT03958045
Small Cell Lung...
Rucaparib and N...
18 Years - University of Kentucky
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02975934
Metastatic Cast...
Rucaparib
Abiraterone ace...
18 Years - pharmaand GmbH
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral ContraceptivesNCT03954366
Neoplasms
Rucaparib
Rosuvastatin
Oral Contracept...
18 Years - pharmaand GmbH
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)NCT03694262
Endometrial Can...
Uterine Carcino...
Rucaparib
Bevacizumab
Atezolizumab
18 Years - Medical College of Wisconsin
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR GenesNCT04171700
Solid Tumor
Rucaparib
18 Years - pharmaand GmbH
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)NCT01482715
Ovarian Cancer
Fallopian Tube ...
Peritoneal Canc...
Advanced Solid ...
Rucaparib
18 Years - pharmaand GmbH
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)NCT03992131
Ovarian Cancer
Triple-negative...
Urothelial Carc...
Solid Tumor
Rucaparib
Lucitanib
Sacituzumab gov...
18 Years - pharmaand GmbH
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsNCT04227522
Ovarian Cancer
Fallopian Tube ...
Primary Periton...
Clear Cell Carc...
Rucaparib
Placebos
18 Years - North Eastern German Society of Gynaecological Oncology
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid TumorNCT03499444
Advanced Solid ...
Rucaparib
20 Years - pharmaand GmbH
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal AdenocarcinomaNCT03995017
Esophagus Cance...
Stomach Cancer,...
Rucaparib
Ramucirumab
Nivolumab
18 Years - University of Kansas Medical Center
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerNCT03101280
Gynecologic Neo...
Atezolizumab
Rucaparib
18 Years - Hoffmann-La Roche
Rucaparib in Nonmetastatic prOstAte With BRCAnessNCT03533946
Prostate Cancer
Rucaparib
18 Years - University of Utah
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)NCT01891344
Ovarian Cancer
Epithelial Ovar...
Fallopian Tube ...
Peritoneal Canc...
Oral rucaparib
18 Years - pharmaand GmbH
Rucaparib and Nivolumab in Patients With Prostate or Endometrial CancerNCT03572478
Prostate Cancer
Endometrial Can...
Rucaparib
Nivolumab
18 Years - University of Chicago
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsNCT01074970
Breast Cancer
Cisplatin
Rucaparib
Cisplatin
18 Years - Hoosier Cancer Research Network
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsNCT02855944
Ovarian Cancer
Epithelial Ovar...
Fallopian Tube ...
Peritoneal Canc...
Chemotherapy
Rucaparib
18 Years - pharmaand GmbH
A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibNCT02873962
Peritoneal Canc...
Ovarian Cancer
Fallopian Tube ...
Bevacizumab
Nivolumab
Rucaparib
18 Years - Dana-Farber Cancer Institute
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyNCT03639935
Biliary Tract C...
Rucaparib
Nivolumab
18 Years - University of Michigan Rogel Cancer Center
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsNCT02855944
Ovarian Cancer
Epithelial Ovar...
Fallopian Tube ...
Peritoneal Canc...
Chemotherapy
Rucaparib
18 Years - pharmaand GmbH
Pharmacokinetic Drug-Drug Interaction Study of RucaparibNCT02740712
Neoplasms
Caffeine
Warfarin
Omeprazole
Midazolam
digoxin
Vitamin K
Rucaparib
18 Years - pharmaand GmbH
Rucaparib and Irinotecan in Cancers With Mutations in DNA RepairNCT03318445
Solid Tumor, Un...
Rucaparib
Irinotecan
18 Years - University of California, San Francisco
A Study to Test Combination Treatments in Participants With Advanced Gastric CancerNCT02935634
Advanced Gastri...
Nivolumab
Ipilimumab
Relatlimab
BMS-986205
Rucaparib
18 Years - Bristol-Myers Squibb
Rucaparib Hepatic Impairment Study in Patients With a Solid TumorNCT03521037
Neoplasms
Rucaparib camsy...
18 Years - pharmaand GmbH
A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaNCT04624178
Leiomyosarcoma
Rucaparib
Nivolumab
18 Years - Memorial Sloan Kettering Cancer Center
Rucaparib in Nonmetastatic prOstAte With BRCAnessNCT03533946
Prostate Cancer
Rucaparib
18 Years - University of Utah
Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or EndometriumNCT03476798
Cervical Cancer
Endometrial Can...
Rucaparib
Bevacizumab
18 Years - 99 YearsUniversity of Oklahoma
A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic SignatureNCT02505048
Metastatic Brea...
rucaparib
18 Years - 99 YearsUNICANCER
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyNCT03639935
Biliary Tract C...
Rucaparib
Nivolumab
18 Years - University of Michigan Rogel Cancer Center
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)NCT03824704
Epithelial Ovar...
Fallopian Tube ...
Primary Periton...
High Grade Sero...
Endometrioid Ad...
Rucaparib
Nivolumab
18 Years - pharmaand GmbH
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsNCT01074970
Breast Cancer
Cisplatin
Rucaparib
Cisplatin
18 Years - Hoosier Cancer Research Network
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialNCT02678182
Adenocarcinoma ...
Adenocarcinoma ...
Adenocarcinoma ...
Capecitabine
MEDI4736
Trastuzumab
Rucaparib
Ramucirumab
18 Years - Royal Marsden NHS Foundation Trust
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: